Braveheart Bio closed a $185 million Series A to launch global registration‑enabling trials for a hypertrophic cardiomyopathy (HCM) candidate licensed from Jiangsu Hengrui. The funding round included top biotech investors and named Biogen’s CEO as board chair, per BioCentury and STAT coverage. The capital will underwrite a pivotal program positioned as a potential challenger to existing therapies. The deal highlights investor appetite for targeted cardiovascular small molecules and the industry’s readiness to fund global late‑stage trials in chronic cardiac indications. Licensing an advanced asset from a large Chinese pharma and raising a sizable Series A illustrate cross‑border dealmaking dynamics in cardio‑drug development.